Results

Total Results: 1,699 records

Showing results for "bmi screening".
Users also searched for: chlamydia

  1. www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/pressure_ulcer_prevention/pu_training-impguide.docx
    October 01, 2017 - Process, Tool 2B Current Process Analysis, Tool 2C Assessing Pressure Ulcer Policies, Tool 2D Assessing Screening … They might include ideas such as universal pressure injury precautions, pressure injury risk screening … policies and practices Implementation Team Leader 2D: Assessing Pressure Ulcer Policies 2E: Assessing Screening … The protocol includes risk factors and the patient’s body mass index (BMI).
  2. www.ahrq.gov/patient-safety/settings/hospital/resource/pressureinjury/guide/apf.html
    October 01, 2017 - The protocol includes risk factors and the patient’s body mass index (BMI).
  3. www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer
    April 11, 2016 - 1.62–2.87)   Cholesterol level (per 1 mmol/L) 0.99 (0.90–1.08) 0.90 (0.77–1.07)   BMI … 1.08–1.19)    Statin     0.67 (0.62–0.71)    PPI     0.84 (0.80–0.88) BMI
  4. www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer-april-2016
    April 11, 2016 - 1.62–2.87)   Cholesterol level (per 1 mmol/L) 0.99 (0.90–1.08) 0.90 (0.77–1.07)   BMI … 1.08–1.19)    Statin     0.67 (0.62–0.71)    PPI     0.84 (0.80–0.88) BMI
  5. effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Effectiveness Research, AHRQ is interested in innovations in drugs and biologics, medical devices, screening … horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments, screening … and length of hospitalizations, and antibiotic use, as well as increasing weight (body mass index [BMI … greater proportion of patients.22 Lumacaftor has demonstrated an ability to increase lung function and BMI
  6. effectivehealthcare-admin.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
    October 01, 2015 - Effectiveness Research, AHRQ is interested in innovations in drugs and biologics, medical devices, screening … horizon scanning, AHRQ’s interests are broad and encompass drugs, devices, procedures, treatments, screening … and length of hospitalizations, and antibiotic use, as well as increasing weight (body mass index [BMI … greater proportion of patients.22 Lumacaftor has demonstrated an ability to increase lung function and BMI
  7. effectivehealthcare.ahrq.gov/sites/default/files/osteoarthritis-knee-update-executive-170505.pdf
    May 01, 2017 - Analytic framework for osteoarthritis of the knee Figure notes: BMI = Body Mass Index; KQ = Key Question … OA (sex, disease subtype, severity (stage/ pain and functional status), fitness, comorbidities, BMI … DistillerSR™ software was used for screening, abstraction, reconciliation, and tracking. … suggested by members of the TEP, peer reviewers, or public reviewers were obtained and underwent the same screening … Our literature flow diagram (Figure B) displays our screening results.
  8. effectivehealthcare-admin.ahrq.gov/sites/default/files/osteoarthritis-knee-update-executive-170505.pdf
    May 01, 2017 - Analytic framework for osteoarthritis of the knee Figure notes: BMI = Body Mass Index; KQ = Key Question … OA (sex, disease subtype, severity (stage/ pain and functional status), fitness, comorbidities, BMI … DistillerSR™ software was used for screening, abstraction, reconciliation, and tracking. … suggested by members of the TEP, peer reviewers, or public reviewers were obtained and underwent the same screening … Our literature flow diagram (Figure B) displays our screening results.
  9. effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_disposition-comments.pdf
    March 10, 2010 - Again report the RR (CI) for each of the BMI groups as it is not clear what you are trying to communicate
  10. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_disposition-comments.pdf
    March 10, 2010 - Again report the RR (CI) for each of the BMI groups as it is not clear what you are trying to communicate
  11. digital.ahrq.gov/sites/default/files/docs/integrating-pros-into-practice-slides-02272024.pdf
    February 27, 2024 - Patient Pre-Operative Factors Considered Age, sex, race BMI, number of medications Medicaid status
  12. effectivehealthcare.ahrq.gov/sites/default/files/pdf/osteoporosis-vibration-therapy_technical-brief.pdf
    January 01, 2020 - Preventive Services Task Force recommends active screening for osteoporosis and early intervention to … Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. … Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice … Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. … femur (femoral neck, trochanter and Ward’s triangle); lumbar spine No NA No NA No NA Balance; BMI
  13. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/osteoporosis-vibration-therapy_technical-brief.pdf
    January 01, 2020 - Preventive Services Task Force recommends active screening for osteoporosis and early intervention to … Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. … Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice … Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. … femur (femoral neck, trochanter and Ward’s triangle); lumbar spine No NA No NA No NA Balance; BMI
  14. www.uspreventiveservicestaskforce.org/uspstf/document/decision-analysis-for-aspirin/aspirin-to-prevent-cardiovascular-disease-and-cancer
    April 11, 2016 - incidence rates used in the model are derived from U.S. data 49 , 50 and reflect contemporary use of screeningBMI = body mass index; BP = blood pressure; CRC = colorectal cancer; CVD = cardiovascular disease; HDL-C … The model run represented here is based on a birth cohort (starting at age 40 y) with hypertension screening … and treatment, cholesterol screening and treatment, and aspirin for primary and secondary prevention—all
  15. www.uspreventiveservicestaskforce.org/uspstf/document/decision-analysis-for-aspirin/aspirin-to-prevent-cardiovascular-disease-and-cancer-april-2016
    April 11, 2016 - incidence rates used in the model are derived from U.S. data 49 , 50 and reflect contemporary use of screeningBMI = body mass index; BP = blood pressure; CRC = colorectal cancer; CVD = cardiovascular disease; HDL-C … The model run represented here is based on a birth cohort (starting at age 40 y) with hypertension screening … and treatment, cholesterol screening and treatment, and aspirin for primary and secondary prevention—all
  16. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
    October 06, 2006 - 60.0 28 PCI 23 23 69.0 17 Myoprotect I126 CABG 21 21 71.0 43 PCI 138 131 60.3 30 BMI … >30 : 17% Octostent127 CABG 142 136 58.9 28 BMI>30 : 15% PCI 50 50 53.3 16 BMI>30 : 26% … Poland130 CABG 50 50 54.1 18 BMI>30 : 20% C-1 Appendix C: Additional Analyses and Evidence … University D-1 Appendix E: Abstraction Forms Appendix E: Abstraction Forms Level One (Screening
  17. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
    October 06, 2006 - 60.0 28 PCI 23 23 69.0 17 Myoprotect I126 CABG 21 21 71.0 43 PCI 138 131 60.3 30 BMI … >30 : 17% Octostent127 CABG 142 136 58.9 28 BMI>30 : 15% PCI 50 50 53.3 16 BMI>30 : 26% … Poland130 CABG 50 50 54.1 18 BMI>30 : 20% C-1 Appendix C: Additional Analyses and Evidence … University D-1 Appendix E: Abstraction Forms Appendix E: Abstraction Forms Level One (Screening
  18. effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - /809 Significant renal impairment; clinically signficant abnormal results of physical exam or lab screening … 1.44) No interactions between any NSAID and aspirin use or coronary heart disease; smoking and BMI … , et al 2005 NR/NR/550 Significant renal impairment; clinically significant abnormalities on screening
  19. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - /809 Significant renal impairment; clinically signficant abnormal results of physical exam or lab screening … 1.44) No interactions between any NSAID and aspirin use or coronary heart disease; smoking and BMI … , et al 2005 NR/NR/550 Significant renal impairment; clinically significant abnormalities on screening
  20. digital.ahrq.gov/sites/default/files/docs/publication/r01hs015169-middleton-final-report-2009.pdf
    January 01, 2009 - Hgb A1c levels as continuous variables; quality of documentation: blood pressure, height, weight, BMI